Replimune Announces Presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 14, 2020 12:29 ET
|
Replimune Group Inc
Initial safety and efficacy data from the single agent RP2 portion of the Phase 1 clinical trial of RP2 alone & in combination with Opdivo® (nivolumab) in patients with solid tumors An update...
Replimune to Participate at the Chardan Virtual 4th Annual Genetic Medicines Conference
October 01, 2020 07:00 ET
|
Replimune Group Inc
WOBURN, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today...
Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update
August 07, 2020 07:00 ET
|
Replimune Group Inc
Clinical proof of principle established with RP1 in combination with Opdivo® for the treatment of immune-responsive tumors supporting registration directed development in CSCC and anti-PD1 refractory...
Replimune to Present at Two Upcoming Investor Conferences
August 04, 2020 07:00 ET
|
Replimune Group Inc
WOBURN, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL) a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today...
Replimune Appoints Andrea Pirzkall, M.D. as Chief Medical Officer
July 22, 2020 07:00 ET
|
Replimune Group Inc
WOBURN, Mass., July 22, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today...
Replimune to Participate at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference
June 17, 2020 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today...
Replimune Announces Pricing of Upsized Public Offering
June 08, 2020 23:20 ET
|
Replimune Group Inc
BOSTON, June 08, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today...
Replimune Announces Proposed Public Offering
June 08, 2020 16:15 ET
|
Replimune Group Inc
BOSTON, June 08, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today...
Replimune Reports Fiscal Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
June 03, 2020 07:15 ET
|
Replimune Group Inc
WOBURN, Mass., June 03, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing a series of oncolytic immuno-gene therapies derived from its Immulytic™...
Replimune Provides RP1 Data Update from its Phase 2 Cohorts in Melanoma and Non-Melanoma Skin Cancer that Strongly Support Replimune’s Ongoing Registration-Directed Clinical Trials with RP1
June 03, 2020 07:00 ET
|
Replimune Group Inc
Multiple Complete Responses Observed in Advanced Cutaneous Squamous Cell Carcinoma High Rate of Deep Responses in Anti-PD-1 / Anti-CTLA-4 Refractory Melanoma Announces Intention to Commence...